Uso de análogos de GLP-1 e Doença Renal Crônica

##plugins.themes.bootstrap3.article.sidebar##

PDF
Publicado Feb 3, 2025
DOI https://doi.org/10.25248/reas.e18990.2025

##plugins.themes.bootstrap3.article.main##

Laura Marangoni Cestaro
Unifev
Letícia Micelli Esperidião Gama
Universidade Nove de Julho - Mauá
Samantha Rodrigues Silva Cupido
Centro Universitário das Américas (CAM)
Maria Fernanda Alves de Moura Leite
Universidade Potiguar (UNP)
Marcella Almeida de Souza
Faculdade de Medicina de Petrópolis (FMP)
Maria Cecília Reis de Paula
Universidade Federal do Rio Grande do Norte (UFRN)
Daniela Kavlac
Faculdade Santa Marcelina (FASM) - Itaquera - SP
Elizandra Franciele Fernandes da Silva
Universidade do Oeste Paulista (Unoeste)
Pedro Vitor Monteiro de Souza
UNIFACISA - Campina Grande - PB
Amanda Carolina Zicatti da Silveira
clínica médica na Pontifícia Universidade Católica de São Paulo

Resumo

Objetivo: Analisar os efeitos dos análogos de GLP-1 na progressão da doença renal crônica (DRC) em pacientes com diabetes tipo 2, seus benefícios e riscos associados ao seu uso. Métodos: Revisão bibliográfica integrativa na base de dados PubMed Central (PMC), através da estratégia de pesquisa: ((GLP-1RA) OR (Glucagon-like peptide-1 receptor agonists) OR (GLP-1)) AND ((Chronic Kidney Disease) OR (CKD)) no período de 2019 a 2024. Após a busca inicial, 585 estudos foram identificados, e submetidos a critérios de seleção. Após a aplicação de critérios de inclusão e exclusão, 18 artigos foram selecionados para compor este estudo. Resultados: Analisou-se o impacto dos análogos de GLP-1 na função renal e progressão da DRC em pacientes com diabetes tipo 2, explorando os mecanismos de proteção renal, avaliando riscos potenciais em diferentes estágios da doença. Considerações finais: Estudos sugerem redução da albuminúria e retardo na queda da Taxa de Filtração Glomerular (TFG), promovendo assim, um prognóstico mais favorável. O uso de análogos de GLP-1 em pacientes DRC é benéfico na proteção renal, entretanto, ainda requer atenção especial em estágios avançados da doença para evitar possíveis complicações.

##plugins.themes.bootstrap3.article.details##

Como Citar
CestaroL. M., GamaL. M. E., CupidoS. R. S., LeiteM. F. A. de M., SouzaM. A. de, PaulaM. C. R. de, KavlacD., SilvaE. F. F. da, SouzaP. V. M. de, & SilveiraA. C. Z. da. (2025). Uso de análogos de GLP-1 e Doença Renal Crônica. Revista Eletrônica Acervo Saúde, 25, e18990. https://doi.org/10.25248/reas.e18990.2025
Edição
v. 25 (2025): Revista Eletrônica Acervo Saúde (ISSN 2178-2091) | Volume 25 | 2025
Seção
Revisão Bibliográfica

Copyright © | Todos os direitos reservados.

A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.

Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.

Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.

Referências

1. ALICIC RZ e NEUMILLER JJ. Incretin Therapies for Patients with Type 2 Diabetes and Chronic Kidney Disease. Journal Clinical Medicine, 2023; 13(1): 201.

2. BHAILÍS ÁM, et al. Diabetic kidney disease: update on clinical management and non-glycaemic effects of newer medications for type 2 diabetes. Therapeutic Advances in Endocrinology and Metabolism, 2021; 12: 1-15.

3. BOMHOL T, et al. The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving Dialysis. Nephron, 2021; 145(1): 27-34.

4. BUENO BA, et al. Semaglutide in type 2 diabetes with chronic kidney disease at high risk of progression—real-world clinical practice. Clinical Kidney Journal, 2022; 15(8): 1593–1600.

5. CHEN JJ, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor: Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease. JAMA Network Open, 2022; 5(3): 221169-221169.

6. COLHOUN HM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nature Medicine, 2024; 30: 2058-2066.

7. DE LUCAS MDG, et al. Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study. Frontiers in Endocrinology, 2023; 14: 1240279.

8. GARCIA LP, et al. Progress in the management of patients with diabetes and chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2022; 31(5): 456-463.

9. KRISANAPAN P, et al. Safety and efficacy of GLP-1 receptor agonists in type 2 diabetes mellitus with advanced and end-stage kidney disease: a systematic review and meta-analysis. Diseases, 2024; 12(1): 14.

10. LI X, et al. Effect of glucagon-like peptide 1 receptor agonists on the renal protection in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes & Metabolism, 2022; 48(5): 101366.

11. LI Y, et al. Comparison of efficacy and safety of three novel hypoglycemic agents in patients with severe diabetic kidney disease: A systematic review and network meta-analysis of randomized controlled trials. Frontiers in Endocrinology, 2022; 13: 1003263.

12. MANN JFE, et al. Potential Kidney protection with liraglutide and semaglutide: exploratory mediation analysis. Diabetes, Obesity and Metabolism, 2021; 23(9): 2058-2066.

13. MAYNE KJ, et al. Detecting and managing the patient with chronic kidney disease in primary care: A review of the latest guidelines. Diabetes, Obesity and Metabolism, 2024; 1(1): 1-12.

14. SCHECHTER M, et al. Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabete: real-world evidence. Cardiovascular Diabetology, 2023; 22(1): 126.

15. SCHOLTEN BJV, et al. The potential of GLP-1 receptor agonists in type 2 diabetes and chronic disease: from randomised trials to clinical pratice. Therapeutic Advances in Endocrinology and Metabolism, 2022; 13: 1-14.

16. SHAMAN AM, et al. Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. Circulation, 2022; 145(8): 575-585.

17. SLOAN LA. Review of glucagon‐like peptide‐1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects. Journal of Diabetes, 2019; 11(12): 938-948.

18. SUZUKI Y, et al. Comparison of estimated glomerular filtration rate change with sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists among people with diabetes: A propensity-score matching study. Diabetes, Obesity and Metabolism, 2024; 26(6): 2422-2430.

19. TREVELLA P, et al. Potential kidney protective effects of glucagon‐like peptide‐1 receptor agonists. Nephrology, 2024; 29: 457-469.

20. TUTTLE KR, et al. Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial. Kidney International Reports, 2024; 9: 2006-2015.

21. WALGORZATA M e NOWICKI M. The impact of GLP‑1 receptor agonist liraglutide on blood pressure profle, hydration, natriuresis in diabetic patients with severely impaired kidney function. Scientific reports, 2024; 14(1): 5002.

22. WILLIAMS DM e EVANS M. Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies. Diabetes Therapy, 2020; 11(10): 2221-2235.

23. ZHAO JZ, et al. Hypoglycemia risk with SGLT2 inhibitors or glucagon-like peptide 1 receptor agonists versus sulfonylureas among medicare insured adults with CKD in the United States. Kidney Medicine, 2022; 4(8): 100510.